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The Allowance of Statistical Sampling in False Claims Act Cases 
I. Health Care Fraud & The False Claims Act: How the Government Responds to the 
Pervasive Problem of Fraud within the U.S. Health Care System 
Health care fraud is a pervasive problem and the False Claims Act (FCA) is an influential 
means for the government to recover funds and prevent future fraudulent behavior and actions by 
health care providers.1 The National Health Care Anti-Fraud Association (NHCAA) estimates 
that health care fraud results in billions of dollars in losses for Americans every year.2 Fraud in 
the health care industry is easily spread across multiple programs, public and private, which 
make it difficult to consistently detect.3 Health care fraud is not a victimless crime it results in 
higher premiums and expenses, reduced coverage, the performance of unnecessary procedures, 
unsafe diagnosis and unsafe procedures performed on patients, and compromised medical files.4 
The Government Accountability Office (GAO) estimated that in fiscal year 2017 there was 
almost $52 billion in improper payments for Medicare.5  In order to combat this fraud involving 
government funds, the Department of Justice successfully uses the FCA. 
The FCA was enacted due to the massive amount of fraud perpetrated against the United 
States during the Civil War.6 The purpose of the FCA was to reclaim payments falsely made by 
wrongdoers and to protect the government from further fraud by deterring false payment 
 
1 THE DEP’T. OF HEALTH AND HUMAN SERV. AND THE U.S. DEP’T. OF JUSTICE, HEALTH CARE FRAUD AND ABUSE 
CONTROL PROGRAM ANNUAL REPORT FOR FISCAL YEAR 2017 (2018), 
https://oig.hhs.gov/publications/docs/hcfac/FY2017-hcfac.pdf.  
2 National Health Care Anti-Fraud Association, The Challenge of Health Care Fraud, 
https://www.nhcaa.org/resources/health-care-anti-fraud-resources/the-challenge-of-health-care-fraud.aspx (last 
visited May 7, 2019). 
3 Id. 
4 Id. 
5 U.S. GOVERNMENT ACCOUNTABILITY OFFICE, GAO-18-660T, MEDICARE: ACTIONS NEEDED TO BETTER MANAGE 
FRAUD RISKS (2018), https://www.gao.gov/products/GAO-18-660T.  
6 Press Release, Dep’t. of Justice, Justice Dep’t. Recovers Over $2.8 Billion from False Claims Act Cases in Fiscal 
Year 2018 (Dec. 21, 2018), available at https://www.justice.gov/opa/pr/justice-department-recovers-over-28-billion-
false-claims-act-cases-fiscal-year-2018. 
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submissions.7 The FCA deters and punishes fraudulent behavior using damages.8 Defendants are 
subject to repayment of claims found to be false (single damages), plus additional damages 
calculated at two or three times the amount of false payments, and penalties of $11,181 to 
$22,363 per claim.9 
In fiscal year 2017 the U.S. Department of Justice (DOJ) received over $3.7 billion from 
judgments and settlements through the FCA.10 Fiscal year 2017 was also the eighth consecutive 
year that the DOJ has received over $3.0 billion.11 In fiscal year 2018, the total recovered by the 
DOJ in civil judgments and settlements was $2.8 billion,12 down from the prior year total. The 
largest recovery area is health care fraud, followed by the financial services industry.13 Besides 
health care and financial services the DOJ receives damages from other industries including 
defense, energy, and telecommunications.14 
According to a 2017 report by the Department of Health and Human Services and the 
Department of Justice Health Care Fraud and Abuse Control Program, during that fiscal year the 
Federal government recovered $2.4 billion in judgments and settlements.15 In fiscal year 2018 
the total recovered was $2.5 billion from the health care industry.16 In fact since 2010, the Civil 
Division’s Commercial Litigation branch has brought in over $2.0 billion every year through 
 
7 1 ERIC M. CARLSON, LONG-TERM CARE ADVOCACY, § 10.06 (Matthew Bender 2018); JOEL M. ANDROPHY & 
REBECCA L. GIBSON, FEDERAL FALSE CLAIMS ACT AND QUI TAM LITIGATION § 6.01, (ALM Media Prop. 2019). 
8 CARLSON, supra note 7. 
9 31 U.S.C. § 3729(a) (2009); 28 C.F.R. § 85.5 (2018). 
10 Press Release, Dep’t. of Justice, Justice Dep’t. Recovers Over $3.7 Billion from False Claims Act Cases in Fiscal 
Year 2017 (Dec. 21, 2017), https://www.justice.gov/opa/pr/justice-department-recovers-over-37-billion-false-
claims-act-cases-fiscal-year-2017. 
11 Suzanne Jaffe Bloom et al., Analysis of the DOJ’s Reported $3.7 Billion in False Claims Act Recoveries in FY 
2017 Reveals Continued Aggressive Use of the False Claims Act by the Government and Qui Tam Relators, 
4 PRATT’S GOVERNMENT CONTRACTING LAW REPORT § 37.03 (LexisNexis A.S. Pratt 2018). 
12 Justice Dep’t. Recovers Over $2.8 Billion from False Claims Act Cases in Fiscal Year 2018, supra note 6. 
13 Bloom et al., supra note 11. 
14 Id; Justice Dep’t. Recovers Over $3.7 Billion from False Claims Act Cases in Fiscal Year 2017, supra note 10. 
15 HEALTH CARE FRAUD AND ABUSE CONTROL PROGRAM ANNUAL REPORT FOR FISCAL YEAR 2017, supra note 1. 
16 Justice Dep’t. Recovers Over $2.8 Billion from False Claims Act Cases in Fiscal Year 2018, supra note 6. 
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judgments or settlements.17 The fiscal year 2017 Agency Financial Report from The Department 
of Health and Human Services reported that the Medicaid improper payment rate was 10.10% 
which amounts to “$36.73 billion in gross improper payments.”18  
Recoveries from the health care industry accounted for sixty-seven percent of the total 
funds received by the federal government from FCA cases in fiscal year 2017.19 Additionally, 
claims from health care fraud represented sixty-eight percent of new matters in 2017.20 FCA 
settlements and judgments in the health care industry involve both individuals and companies, 
working within the pharmaceutical industry, at medical device manufacturers, hospitals, 
pharmacies, laboratories, and nursing homes.21 From 2010 to 2017 under the FCA the DOJ 
recovered $20.4 billion from the health care industry.22 Since the amendments to the FCA in 
1986 through fiscal year 2018 the DOJ has recovered in civil judgments and settlements $59 
billion.23 
The government is increasingly turning towards statistical sampling due to the size of the 
universe of claims involved in FCA health care cases24, the costs associated with individual 
reviews of each claim25, and the lack of documentation26. The universe of claims (and patients) 
will continue to rise as the population ages and by the year 2030 the U.S. Census Bureau 
 
17 Id. 
18 HEALTH CARE FRAUD AND ABUSE CONTROL PROGRAM ANNUAL REPORT FOR FISCAL YEAR 2017, supra note 1, at 54. 
19 Bloom et al., supra note 11. 
20 Bloom et al., supra note 11. 
21 Justice Dep’t. Recovers Over $2.8 Billion from False Claims Act Cases in Fiscal Year 2018, supra note 6; see 
also Bloom et al., supra note 11. 
22 Bloom et al., supra note 11. 
23 Justice Dep’t. Recovers Over $2.8 Billion from False Claims Act Cases in Fiscal Year 2018, supra note 6. 
24 United States ex rel. Martin v. Life Care Ctrs. of America, Inc., 114 F. Supp. 3d 549, 560 (E.D. Tenn. 2014); 
United States ex rel. Michaels v. Agape Senior Comty., Inc.,No. 0:12-3466-JFA,  2015 U.S. Dist. LEXIS 82379, at 
*3-4 (S.C. June 25, 2015).  
25 United States ex rel. Michaels, 2015 U.S. Dist. LEXIS 82379, at *3-4. 
26 Id. at 18-19. 
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estimates that 1 out of every 5 Americans will be age 65 or older.27 Also, since the 1986 
amendments to the FCA the health care industry has been impacted by the rise in technology, 
this is predicted to continue.28 Some Courts have been willing to allow the use of statistical 
sampling as the quantity of claims has increased and the cost of reviewing claims has risen.29  
Currently there remains an open controversy of whether statistical sampling can or should 
be used by the government in health care FCA cases. District Courts have ruled for and against 
the use of statistical sampling, but to date no Court of Appeals has answered the specific 
question of whether statistical sampling is allowable or not allowable. Many commenters and 
legal analysts have framed the cases into two basic groups: those pro-statistical sampling and 
those anti-statistical sampling. In complex cases, such as those involving health care fraud, and 
the complexity of statistical sampling, the facts and circumstances of each case and analysis 
make the issue itself more complicated than simply a favorable or unfavorable view of statistical 
sampling. 
II. FCA Elements and Damages 
A. FCA Elements 
The False Claims Act provides under 31 U.S.C. S. § 3729(a)(1):  
(A) “any person who knowingly presents, or causes to be presented, 
a false or fraudulent claim for payment or approval;” or (B) 
“knowingly makes, uses, or causes to be made or used, a false record 
or statement material to a false or fraudulent claim” is liable to the 
U.S. Government.30  
 
 
27 U.S. CENSUS BUREAU, OLDER PEOPLE PROJECTED TO OUTNUMBER CHILDREN FOR THE FIRST TIME IN U.S. HISTORY 
(Sep. 2018), https://www.census.gov/newsroom/press-releases/2018/cb18-41-population-projections.html. 
28 Deloitte, 2019 Global Health Care Outlook, at 19-20 (2019); https://www2.deloitte.com/us/en/pages/life-sciences-
and-health-care/articles/us-and-global-health-care-industry-trends-outlook.html.  
29 United States ex rel. Martin, 114 F. Supp. 3d at 560; see also JOEL M. ANDROPHY & REBECCA L. GIBSON, 
FEDERAL FALSE CLAIMS ACT AND QUI TAM LITIGATION § 9A.04, (ALM Media Prop. 2019). 
30 31 U.S.C. S. § 3729 (a)(1)(A)(2009). 
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In order to meet their burden under the FCA, the government must prove that the person 
had knowledge, that the claim was false (falsity), and that the claim was material (materiality).31 
Knowingly or knowing is also defined by the statute as meaning that a person: “(i) has actual 
knowledge of the information; (ii) acts in deliberate ignorance of the truth or falsity of the 
information; or (iii) acts in reckless disregard of the truth or falsity of the information.”32 Further, 
there is no requirement that the person have the specific intent to defraud the government.33  
Falsity requires that the government show that the claim filed was false.34 The issue of 
falsity is separate from proving that the defendant had knowledge of the fraud or acted 
recklessly.35 The government has the burden in FCA cases to prove that the claim itself was 
false.36 Material, as defined by statute, means “having a natural tendency to influence, or be 
capable of influencing, the payment or receipt of money or property.”37  The claim must be 
material, if a claim is not material then there is no FCA liability. For a claim to be material, as 
defined above by the statute, it must influence the payment for a claim, if there is no influence 
upon payment then the claim is not material. 38 So, if the government pays a claim while 
knowing that the claim has violated certain requirements, this can be evidence that the violated 
requirement was not material and therefore no liability.39  
Under the FCA there is a direct link to liability and damages by statutory provision. The 
FCA states: 
 
31 United States ex rel. Martin, 114 F. Supp. 3d at 565-69. 
32 31 U.S.C. S. § 3729 (b) (1) (A) (2009). 
33 31 U.S.C. S. § 3729 (b) (1) (B) (2009). 
34 31 U.S.C. S. § 3729 (b) (1) (A) (2009). 
35 United States ex rel. Wall v. Vista Hospice Care, Inc., No. 3:07-cv-00604-M, 2016 U.S. Dist. LEXIS 80160, at 
*63 (N.D. Tex. June 20, 2016). 
36 Id. 
37 31 U.S.C. S. § 3729 (b) (4) (2009). 
38 31 U.S.C. S. § 3729 (b) (4) (2009); see also United States ex rel. Martin v. Life Care Ctrs. of America, Inc., 114 F. 
Supp. 3d 549, 569 (E.D. Tenn. 2014). 
39 CARLSON, supra note 7. 
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In general. Subject to paragraph (2), any person who. . . knowingly makes, uses, or 
causes to be made or used, a false record or statement material to an obligation to 
pay or transmit money or property to the Government, or knowingly conceals or 
knowingly and improperly avoids or decreases an obligation to pay or transmit 
money or property to the Government, is liable to the United States Government 
for a civil penalty of not less than $ 5,000 and not more than $ 10,000, as adjusted 
by the Federal Civil Penalties Inflation Adjustment Act of 1990 (28 U.S.C. 
2461note; Public Law 104-410), plus 3 times the amount of damages which the 
Government sustains because of the act of that person.40 
 
Once the government has met their burden of proving that a defendant knowingly 
submitted false claims that were material, then the government is entitled to damages. 
As the total quantity of claims has increased along, with rising costs of claim-by-claim 
review, the government has attempted to utilize statistical sampling and extrapolation to prove 
liability and calculate the total amount of damages.41 When a health care provider has submitted 
hundreds or thousands of claims, the use of statistical sampling will save both the time and cost 
of conducting an individual claim-by-claim review.42 In some of the recent court cases where the 
government has attempted to utilize statistical sampling the number of claims submitted by a 
defendant has ranged between 25,000 to almost 155,000 claims.43 With such large universes of 
claims there would be great expenditures of time and resources to prove each claim false.44 
Further, the cost of reviewing claims by medical experts has risen. In one nursing home case, in 
which the government attempted to use statistical sampling, the government’s estimate was that 
one expert would need four to nine hours to adequately review a patient’s file and the expert’s 
 
40 31 U.S.C.S § 3729 (a)(1)(G). 
41 United States ex rel. Martin v. Life Care Ctrs. of America, Inc., 114 F. Supp. 3d 549, 560 (E.D. Tenn. 2014); 
United States ex rel. Michaels v. Agape Senior Comty., Inc., No. 0:12-3466-JFA, 2015 U.S. Dist. LEXIS 82379, at 
*3-4 (S.C. June 25, 2015). 
42 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF INSPECTOR GENERAL, STATISTICAL SAMPLING: 
A TOOLKIT FOR MFCUS, https://oig.hhs.gov/fraud/medicaid-fraud-control-units-
mfcu/files/MFCU%20Sampling%20Guidance%20Final.pdf (last visited May 7, 2019). 
43 United States ex rel. Martin, 114 F. Supp. 3d at 556; United States ex rel. Michaels,  2015 U.S. Dist. LEXIS 
82379, at *3; United States v. Robinson, No. 13-cv-27-GFVT, 2015 WL 1479396, at*6 (E.D. Ky. Mar. 31, 2015). 
44 United States ex rel. Martin, 114 F. Supp. 3d at 565. 
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fee was $400 per hour which totaled between $1,600 to $3,600 per patient.45  In that individual 
case the total expense would range “between $16.2 million and $36.5 million.”46 The lack of 
documentation also drives the government’s attempts to use statistical sampling.47  
In addition to using statistical sampling to establish liability and damages with larger 
universes of claims and increased resource devotion, the government has attempted to establish 
knowledge and falsity using sample claims and then extrapolating.48 Given that many providers 
are now larger organizations that have multiple locations and multiple physicians making 
determinations, it is more practical for the government to use statistical sampling and 
extrapolation.49 Over time there have been changes to government programs which increased the 
total number of individuals covered, as well as the creation of anti-fraud programs and incentives 
by the Centers for Medicare and Medicaid.50 These changes have impacted the desire to utilize 
statistical sampling. Lastly, the statutory language of the FCA does not prevent the government, 
or any party, from using statistical sampling.51  
III. Federal Rules of Evidence and the Daubert Standard 
The use of statistical sampling will involve the use of expert evidence and therefore must 
comply with Federal Rules of Evidence, specifically rule 702, which outlines four elements that 
guide the Court in admission of expert evidence: “(a) the expert’s scientific, technical, or other 
specialized knowledge will help the trier of fact to understand the evidence or to determine a fact 
 
45 United States ex rel. Michaels, 2015 U.S. Dist. LEXIS 82379, at *3. 
46 Id. at *3-4. 
47 Id. at *19. 
48 United States ex rel. Martin, 114 F. Supp. 3d at 565-68. 
49 United States ex rel. Wall v. Vista Hospice Care, Inc., No. 3:07-cv-00604-M, 2016 U.S. Dist. LEXIS 80160 (N.D. 
Tex. June 20, 2016). 
50 CENTERS FOR MEDICARE & MEDICAID SERVICES: CENTER FOR PROGRAM INTEGRITY, https://www.cms.gov/About-
CMS/Components/CPI/CPI-Landing.html (last visited May 10, 2019); see MEDICARE: ACTIONS NEEDED TO BETTER 
MANAGE FRAUD RISKS (2018), supra note 5; see also 42 U.S.C. § 1395ddd(f)(3) (2016). 
51 United States ex rel. Martin, 114 F. Supp. 3d at 571. 
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in issue; (b) the testimony is based on sufficient facts or data; (c) the testimony is the product of 
reliable principles and methods; and (d) the expert has reliably applied the principles and 
methods to the facts of the case.”52 Rule 702 was amended to codify the factors outlined by the 
Supreme Court in Daubert v. Merrell Dow Pharmaceutical, Inc.53 The Daubert Factors for 
assessing expert evidence include: (1) whether the theory or technique in question can be and has 
been tested; (2) whether it has been subjected to peer review and publication; (3) its known or 
potential error rate; (4) the existence and maintenance of standards controlling its operation; and 
(5) whether it has attracted widespread acceptance within a relevant scientific community.54  
Reliable expert testimony using statistical sampling requires that the underlying 
methodologies be based on widely and generally accepted methods.55 Courts have critiqued 
several factors within statistical sampling based upon the analysis of the data, the presentation, or 
the accumulation of the data that impacts the reliability of the methodologies.56 These factors 
include:  
The selection of an inappropriate control population for comparison with the test 
population. The inclusion of irrelevant data. The use of a data base that is too small. 
The improper combination of categories into a single category, to create an 
impression at odds with the actual results of the study. The failure to account for 
potential systemic errors, such as selective recall in respondents providing the data 
base that the statistician analyzed.57 
 
    Based on statutory elements and Supreme Court guidance, expert evidence such as 
statistical sampling and testimony by the experts who perform such analysis will have to 
comply with those elements and be admitted by the Court. The government/relator has the 
 
52 FED. R. EVID. 702. 
53 United States ex rel. Loughren v. Unum Provident Corp., 604 F. Supp. 2d 259, 263 (D. Mass. 2009); see FED. R. 
EVID. 702. Notes of Advisory Committee over 2000 amendments. 
54 Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 592-95 (1993). 
55 4 JACK B. WEINSTEIN & MARGARET A. BERGER, WEINSTEIN’S FEDERAL EVIDENCE, § 702.06 (Mark S. Brodin, 
ed., Matthew Bender 2 ed. 2019). 
56 Id. 
57 Id. 
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burden of proving that their expert evidence and expert witness are reliable.58 Defendants 
can challenge experts reliability using the Daubert factors.59 
IV. Statistical Sampling in the Law 
Statistical sampling has been used in a wide variety of cases outside of health care fraud, 
such as “antitrust, employment discrimination, toxic torts, and voting rights cases.”60 Statistical 
analysis and expert testimony has been used in many cases to prove: 
[F]acially neutral practices had a disparate impact on a protected class in 
employment discrimination cases . . . That the pricing and sales activities of 
competitive distributors of chlorine indicated circumstantially that they were 
engaged in collusive bidding and pricing in violation of the antitrust laws. That the 
amount of pseudoephedrine products purchased by defendant for resale in his 
convenience store, compared to the expected legitimate consumer demand, tended 
to show that he was engaged in criminal activity, rather than legitimate retail sales. 
That defendant drug manufacturer’s fraudulent marketing campaigns to physicians 
causally affected their prescribing of defendant’s drug for off-label uses.61 
Expert witness testimony by statistical experts is admissible when the expert witness is 
“qualified to give expert testimony in the field of statistics (see § 702.04), the testimony will be 
helpful to the trier of fact (see § 702.03), and the testimony is reliable and “fits” the case (see 
§ 702.05).”62 Expert testimony for statistical analysis will be allowed only if it is probative on the 
issue that is determinative for the trier of fact.63 Many times the battle over the use of statistical 
sampling in legal cases will be over the weight given rather than admissibility, but studies may 
be inadmissible because they were poorly executed, the method was inappropriate, or the 
sampling utilized data that is not reasonably relied upon by experts.64 Generally though statistical 
 
58 United States ex rel. Loughren, 604 F. Supp. 2d at 269.  
59 United States v. Paulus, 894 F.3d 267, 273 (6th Circuit. 2018). 
60 David H. Kaye & David A. Freedman, Reference Guide on Statistics, in REFERENCE MANUAL ON SCIENTIFIC 
EVIDENCE 211, 213 (3rd ed. 2011). 
61 Weinstein, supra note 55. 
62 Weinstein, supra note 55. 
63 Weinstein, supra note 55. 
64 Kaye, supra note 60, at 214. 
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studies will be admitted if they address material issues and fully comply with the Federal Rules 
of Evidence which allows for admission.65  
A sound statistical analysis should ensure that measurements are reliable, valid, and that 
the sample is representative of the population as a whole.66 In order to avoid selection bias 
samples should be randomized, and if there is bias the statistician will need to find a model that 
is better suited for the data or make changes to their design model.67 When working with data 
that spans a lengthy period of time the statistician should verify what, if any, changes have been 
made to collection of the data over that period of time or whether definitions that directly impact 
data collection have been updated.68 In health care fraud cases diagnosing criteria and medical 
definitions will be especially important when reviewing data and determining variables over any 
extended period of time. 
Sampling was statutory authorized in 2003 when Congress passed the Medicare 
Prescription Drug, Improvement and Modernization Act which established the Medicare 
Integrity Program.69 This program allows Medicare contractors to request medical records, 
supporting documentation, and allows for extrapolation of sampling to determine the total 
amount of overpayments by Medicare in certain circumstances.70 Currently statistical sampling 
within the health care context has expanded from its long history of use in the administrative 
setting to use within federal Courts under the FCA.71   
 
65 Kaye, supra note 60, at 214. 
66 Kaye, supra note 60, at 217-27. 
67 Kaye, supra note 60, at 225-46. 
68 Kaye, supra note 60, at 231. 
69 Katie Pawlitz and Greg Russo, Proactively Responding to Government Investigations using Data Analytics: An 
Examination of Data Considerations in the Post-Acute Context, 29 HEALTH LAYERS 23 (June 2017). 
70 Id.  
71 Id.  
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Statistical sampling and extrapolation in administrative cases is statutorily authorized 
when “there is a sustained or high level of payment error” or “documented educational 
intervention has failed to correct the payment error.”72 Judicial review of administrative agency 
actions is governed by the Administrative Procedure Act (APA).73 The standard of review is 
deferential to the agency’s expertise and allows the court to only set aside agency decisions that 
are “arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.”74 The 
court may not substitute its own judgement for that of the administrative agency.75 Allowing the 
use of statistical sampling and extrapolation in an administrative sampling does not simply 
transfer to using statistical sampling in FCA cases that are heard directly by District Courts. A 
District Court hearing an FCA case will have to apply its own judgment and will have to follow 
the Federal Rules of Civil Procedure in evaluating claims, not follow the APA standard for 
judicial review.76 
If an expert witness is relying on a statistical analysis a Court should inquire as to the use 
of the analysis in the case at hand and why a particular model was chosen.77 The Court needs to 
consider whether it has enough information and details about the model and methodology that 
the analysis could be replicated and whether the Court can determine that the expert’s choices 
were reasonable.78 In addition to the model chosen the Court should inquire about the variables 
included, since the Court decides if a model is appropriate.79  The Court should question which 
variables were included, why certain models include or do not include certain variables, and 
 
72 42 U.S.C. § 1395ddd(f)(3) (2016).  
73 Gentiva Health Care Corp. v. Sebelius, 857 F. Supp. 2d 1, 6 (D.D.C. April 6, 2012). 
74 5 U.S.C. § 706 (2)(A). 
75 Gentiva Health Care Corp., 857 F. Supp. 2d at 6. 
76 Id. 
77 Kaye, supra note 60, at 271. 
78 Daniel Rubinfeld, Reference Guide on Multiple Regression, in REFERENCE MANUAL ON SCIENTIFIC EVIDENCE 303, 
330 (3rd ed. 2011).  
79 Kaye, supra note 60, at 272. 
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whether any variables included were tainted.80 The expert should be prepared to explain to the 
Court why they chose that particular model and if there are any other suitable models from which 
they could have chosen.81 In order to minimize disputes over statistical analysis an expert should 
provide the Court with: clearly stated objectives, definitions of variables, the sample parameters, 
what methods were utilized in calculating a sample, any deficiencies with the data or method, 
and measurements over error calculations.82 
It is a matter of law whether or not the Court will allow the government or the defendant 
to use statistical sampling in a case,83 but once allowed the fact finder decides which experts to 
believe and which evidence to give more weight. Given the technical nature of health care fraud 
cases and the science behind statistical analysis multiple experts will be the norm in these cases84 
and the jury will, as they do in other types of cases, give weight to testimony and the evidence 
presented. 
V. History of FCA Cases Using Statistical Sampling 
In the past few years there have been several cases where the government or relator has 
attempted to use statistical analysis in an FCA case before a District Court. Some District Courts 
have allowed the use of statistical sampling, while others have not allowed the use of statistical 
sampling.  
A. Cases that Have Not Allowed Statistical Sampling 
The following District Court cases have not allowed statistical sampling in FCA claim 
cases. A 2016 case in Texas, United States ex rel. Wall v. Vista Hospice Care, Inc., involved the 
 
80 Kaye, supra note 60, at 272. 
81 Rubinfeld, supra note 78, at 317.  
82 Rubinfeld, supra note 78, at 331-32. 
83 ANDROPHY § 9A.04, supra note 29. 
84 Kaye, supra note 60, at 215. 
 13 
determinations by physicians employed by the hospice care facility of whether a patient was 
eligible for Medicare’s hospice benefit, the requirement for such benefit being that the individual 
is terminally ill.85 A patient is terminally ill if their life expectancy is six months or less.86 The 
Centers for Medicare and Medicaid Services (CMS) have advised physicians that determining 
life expectancy is not exact and that there is no risk to the physician for certifying a patient for 
hospice care so long as the physician believes the patient is terminally ill.87 The patient 
population was identified by the statistician hired by the relator as consisting of 12,000 patients 
over an eight year period.88 The statistician then selected a sample of 291 patients for the expert 
in hospice and palliative care to review.89 The relator argued that the sampling and extrapolation 
were “sufficient to show both damages and liability” in this case, but the court came to the 
opposite conclusion that it could not establish liability for fraud.90 The Court concluded that 
statistical sampling is appropriate when the sample data can prove the elements of the specific 
claim reliably.91 Here the Court found the expert witness and the statistical methodology were 
“fundamentally flawed” since variables identified as important were not controlled nor was the 
sample randomly selected.92 Further the Court stated that proof regarding one individual claim 
does not give rise to proof that other claims were false due to the differences in claims based on 
individual patient’s condition, treatment, and physician.93 The Court did acknowledge other 
cases where variables were controlled, and that the statistician in this case could have done the 
 
85 United States ex rel. Wall v. Vista Hospice Care, Inc., No. 3:07-cv-00604-M, 2016 U.S. Dist. LEXIS 80160, at 
*6-9 (N.D. Tex. June 20, 2016). 
86 Id. 
87 Id. at *9. 
88 Id. at *31. 
89 Id. at *32. 
90 Id. at *35. 
91 Id. at *40-41. 
92 Id. at *42-43. 
93 Id. at *42. 
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same but did not.94 Based upon the lack of reliability of the statistical sampling, since the sample 
was not randomized based on the whole population and variables were not controlled, the nature 
of the subjective determinations for hospice placement, and that the statistical sampling would 
need to prove all elements of a FCA claim, the Court did not allow extrapolation.95 
In a similar case also involving hospice care and inpatient services at a nursing home, the 
Court did not allow the use of statistical sampling to prove liability for damages.96 In United 
States ex rel. Michaels v. Agape Senior Community, Inc., the Court felt that determining whether 
services for nursing home patients were medically necessary was a highly-fact intensive inquiry 
that involved review of patient files individually.97  The relators in this case claimed that Agape 
submitted false claims for hospice related services.98 The defendants claimed that during the 
period in question there were 53,280 claims submitted for 19,820 patients.99 The relator claimed 
that there were 61,643 claims for 10,166 patients.100 The relator also informed the Court that it 
would cost “between $16.2 million and $36.5 million” to have two experts review each patient’s 
chart for anywhere from four to nine hours, at a hourly rate of $400.101 The Court separated this 
case from another recent non-health care case where the evidence was no longer available and 
therefore statistical sampling was the only way for the government/relator to prove damages.102 
Further, the Court did not find that statistical sampling could not be used in other cases, simply 
that this case was not “suited for statistical sampling.”103  
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In United States v. AseraCare, Inc. the government argued that AseraCare violated the 
FCA by presenting false claims for payment when certifying patients for hospice care.104 The 
defendant operated hospice care facilities in nineteen states and the defendant’s sixty facilities 
accounted for almost 10,000 patient admissions each year.105  During the relevant period it was 
determined that the universe of patients was 2,181 patients.106 The government hired an expert to 
review 233 of the patient claims and found that 124 of the 233 claims were false.107 The 
government sought to extrapolate the sampling finding to the entire universe.108 The Court 
initially found that statistical evidence was evidence that the jury should evaluate and the jury 
should accord the weight to be given to both the government’s evidence and the defendant’s 
evidence.109 However, the case quickly became centered on whether using only the expert 
witness’ testimony over his sampling of the 233 claims was enough to prove falsity without more 
objective evidence.110 Eventually the defendant was granted summary judgment since the 
government did not use any other testimony other than one clinician’s opinion on whether the 
patients were eligible for hospice care.111 The Court found that as a matter of law mere 
“contradiction based on clinical judgment or opinion alone cannot constitute falsity under the 
FCA.”112 
In United States ex rel. Trim v. McKean, a medical coding company was charged with 
submitting false claims to a Pennsylvania Medicare administrative program along with Medicaid 
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programs in Arizona and Oregon.113 The Court found that the audits were insufficient to form a 
statistical sample of the universe of claims, that the audits were not reliable nor an accurate 
representation of the universe of claims, and therefore the court was unwilling to extrapolate the 
audit findings.114 Considering that the charts, largely handwritten and illegible, in Pennsylvania 
were not representative of the universe of claims the Court was unwilling to use that audit to 
extrapolate.115 The Oregon audit was tainted by the opportunity for false claims to be recovered 
once they were notified of the current lawsuit, the Court was concerned with the objectiveness of 
the audit.116 The experts who were responsible for the Arizona audit did not testify, which 
factored into the Court’s decision to not extrapolate based on that audit.117 
A defendant’s motion to exclude the government’s expert testimony over its statistical 
sampling was allowed in United States ex rel. Loughren v. UnumProvident Corp.118 In 
Loughren, the plaintiff claimed that the corporation urged claimants to file for Social Security 
Disability benefits that the corporation knew they did not qualify for based upon the statutory 
requirements for disability.119 The claims took place in a ten year span from January 1997 to July 
2007 and include 468,641 claims.120 The Court concluded that providing the statistical 
methodology was reliable, then extrapolation was reasonable since there was enough evidence at 
trial that a jury could reasonably find that the corporation violated the FCA.121 However, the 
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Court went on to find that the statistical sampling was unreliable due to overlapping cohorts and 
lack of secondary resources or peer reviewed literature to support the methodology utilized.122 
In United States ex rel. El-Amin v. George Washington Univ., the Court did not allow the 
relator to try the case using statistical sampling. The complaint alleged that over six years the 
defendant submitted false claims to Medicare for anesthesia services that had been performed by 
licensed physicians, but had instead been performed by other staff members.123 Of particular 
concern to the court was the fact that the relator was unable to determine the universe of claims, 
instead offering that it could be between 5,000 and 15,000 claims.124 The Court ended up 
denying the motion to use statistical sampling because there was a lack of a definite universe of 
claims, plus the motion was filed in 2008 after a long discovery period that began when the case 
was filed in 1995.125 The Court also noted that the decision to use statistical sampling so close to 
trial would be unfair to the defendant who, like the relator, has not secured an expert witness nor 
determined the universe of claims.126 
B. Cases that Have Allowed Statistical Sampling 
While some courts have not allowed a relator or the government to proceed with their 
statistical sampling, other courts have found it appropriate. In considering summary judgment of 
the government’s use of statistical sampling only, the Court in United States ex rel. Martin v. 
Life Care Ctrs. Of America, Inc. denied the defendant’s motion.127 The government asserted that 
the defendant up-coded and also billed for medically unnecessary services.128 At issue were 
54,396 patient admissions that total 154,621 claims that occurred at eighty-two facilities between 
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January 2006 until January 2012.129 The Government wanted to use a random sample of 400 
admissions and then extrapolate those findings to the universe of claims.130 The Court concluded 
that preventing statistical sampling and relying only upon individual claim-by-claim review 
under the FCA would not deter fraudulent behavior, which is inconsistent with the purpose and 
history of the FCA.131 The evidence is best left to the jury to determine the weight to be given to 
the government’s statistical sampling, extrapolation, and the defendant’s evidence.132  
In United States v. Cabrera-Diaz, the defendant never responded nor appeared in the case 
in which he was charged with over billing Medicare for anesthesia time.133 An audit for two 
years, 1994 and 1995, revealed that in the first year the defendant physician over billed for 
77,899 minutes and in the second year billed Medicare another 69,943 minutes of “overstated, 
falsely claimed, unsupported or undocumented anesthesia time.”134 The Medicare contractor in 
this case, based upon the Medicare guidelines for methodology, selected a random sample of 230 
claims from 1994 and 231 claims from 1995.135 The results from these two samples were then 
extrapolated to the universe of claims.136 The final result of the extrapolation was a total of 
$237,600.39 of overpaid time in 1994 and $211,773.89 for 1995.137 The court cited to other cases 
that allowed the use of statistical sampling and ultimately used the sampling and extrapolation 
figures when entering default judgment against the defendant physician.138  
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In United States v. Robinson, the physician, an optometrist, and his company were 
charged with claims under the FCA for submitting claims for medically unnecessary or 
unreasonable services or for services not actually provided.139 Dr. Robinson traveled to fourteen 
nursing homes and provided services to patients every four to six weeks.140 The universe of 
claims was determined to be 25,779 claims for the relevant period and the government’s expert 
witness reviewed a random sample of 30 examination files.141 The government sought to use 
statistical sampling and extrapolation, but the defendant argued that the use was improper as a 
matter of law.142 The Court concluded that the use of statistical sampling and extrapolation were 
not improper as a matter of law and that the jury should determine the weight given to the 
evidence presented over the statistical analysis.143  
In United States v. Fadul, the physician and his mobile diagnostic business were charged 
with submitting false claims under Medicare and Medicaid for nursing home patients.144 The 
company’s billing system would bill for two codes when one imaging service was performed.145 
So when a technician logged an abdominal ultrasound, the company billed the patient’s 
insurance for both an abdominal and retroperitoneal ultrasound.146 Additionally, when a 
technician logged a bilateral lower extremity venous study or a unilateral lower extremity venous 
study the company would bill for both a venous duplex ultrasound, bilateral and the non-invasive 
physiologic study of extremity veins.147 During the time from 2004 to 2009 the physician and his 
company received $145,010.99 from Medicare and $11,544.24 from Medicaid for services under 
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the retroperitoneal ultrasound that was not performed.148 Additionally, the defendant received 
$588,521.61 from Medicare and $17,433.47 from Medicaid for the double coding of the venous 
studies.149 The Court did not grant summary judgment for the FCA claims against the physician, 
but did grant judgment for a claim for payment by mistake of fact.150 The court accepted the 
government’s calculation of damages based upon statistical sampling and extrapolation as 152 of 
the 551 claims could not be obtained.151 
In United States ex rel. Doe v. DeGregorio, the defendant was charged with filing false 
and fraudulent claims to Medicare that resulted in over $17 million in payments to the 
company.152 The Court allowed the evidence done by audits and small samples to suffice in 
holding the defendant’s property to pay his debts.153 
VI. Analysis of Successes and Failures of Statistical Sampling in FCA Health care 
cases 
A. Why Statistical Sampling Has Succeeded in Some Cases 
To date, some District Courts have allowed statistical sampling to be used in proving 
falsity, liability, damages, defended against due process concerns, and balanced concerns over 
methodology and clinical judgment. In United States ex rel. Martin v. Life Care Centers of 
America, Inc., the government claimed that Life Care Centers of America, Inc. increased patients 
therapy time during assessment periods and billed for unnecessary services.154In Martin, the 
Court found that the government could specify the individual claims, but that the universe of 
claims was large and would be burdensome on the government to do so for each and every 
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claim.155 Further the Court did not find that falsity could not be established nor that each claim 
needed to be individually reviewed.156 The Court did not find the argument persuasive that each 
of the fifteen plus factors identified as part of an analysis of the patient’s care were unique to 
each patient and therefore the use of statistical sampling was precluded.157 The Court concluded 
that statistical sampling was appropriate for such a situation, if all claims were identical then 
there would be no need for statistical sampling.158 During a trial the defense can cross-examine 
the government’s expert witness on qualifications, statistical method used, acceptable methods 
from which to choose, and research to support opinions.159 The defense can also call their own 
witnesses and present their own statistical sampling and analysis for liability and damages.160 
Further, while Courts decide on whether statistical sampling can be used, the fact finder decides 
on the credibility of the witnesses and evidence offered by both parties.161  
When the defendant in United States v. Robinson challenged the use of statistical 
sampling to extrapolate for both liability and damages as improper as a matter of law, the Court 
found that the use of statistical sampling nor using a sample to extrapolate was improper as a 
matter of law.162 Further, in that case the Court found that to use statistical sampling the sample 
must be representative and the methodology must be valid, but the defendant had not challenged 
the sampling methodology.163 The Court determined that “proof of an objective falsehood is not 
the only means of establishing an FCA claim.”164 In quoting United States ex rel. Wall, the Court 
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stated that falsity can be proved “by an express false certification or it can also be established 
through a theory of implied certification,” when the defendant did not comply with the 
regulatory requirements when billing.165 Here, the government has to show that the defendant did 
not comply with the statute when submitting payments.166 Having the government’s medical 
expert review the sample of patient files is more properly framed as whether it creates an “issue 
of material fact” that should go to the jury not whether it proves falsity when moving for 
summary judgment.167 The defendant could cite to no authority that stated that expert medical 
opinions were not sufficient evidence when determining whether medical treatment was 
necessary.168 
In United States v. Cabrera-Diaz, the Court used statistical sampling in an audit of the 
defendant’s submissions for Medicare payment for anesthesia services.169 The results of the audit 
where extrapolated to the entire universe of claims to determine the amount of overpayment due 
to Medicare.170 The Court went on to use the amounts of overpayment and total number of 
claims determined from the extrapolation of the statistical sample to the total universe of claims 
to determine the total amount of damages.171 The Court effectively used statistical sampling and 
extrapolation to find both liability and damages.172 
Statistical sampling has been allowed to calculate damages in many types of cases, 
including health care fraud cases using the FCA when it is not practical to conduct a claim-by-
claim review.173 In United States v. Fadul, the Court found that statistical sampling and 
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extrapolation is “a viable method of proving damages in cases . . . where a claim-by-claim 
review is not practical.”174 In Fadul, the Court allowed the use of statistical sampling and 
extrapolation to grant summary judgment for the common law claim of “payment by mistake of 
fact” while not granting summary judgment on the FCA claims.175 In United States ex rel. Doe v. 
DeGregorio, the Court allowed audits and extrapolation to calculate total potential damages 
when the Court issued Prejudgment Writs of Attachment and Sequestration on property owned 
by the defendant.176  
B. Why Statistical Sampling Has Failed in Some Cases 
    In United States ex rel. Wall v. Vista Hospice Care, Inc., the Court would not allow the 
relator to establish liability under the FCA since the underlying facts of the case involved a 
physician’s subjective judgment on hospice care based upon an individual patient’s medical 
file.177 The Court concluded that statistical sampling is appropriate when the sample data can 
prove the elements of the specific claim reliably, but that was not the situation in the present 
case.178 Further, the Court found the expert witness and the statistical methodology were flawed 
and stated that proof regarding one individual claim does not give rise to proof that other claims 
were false due to the differences in claims based on individual patient’s condition, treatment, and 
physician.179  Here the Court did not believe that the expert selected the “relevant variables” nor 
did he “select a random sample.”180  The Court acknowledged that variables, such as individual 
patient conditions, treatment, physician, etc., could be controlled, but in this case had not been 
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and along with the underlying subjective nature of the clinical determination extrapolation was 
not allowed.181  Further, the Court did not allow the government to prove falsity with only 
another expert’s clinical judgments, instead requiring evidence of an objective fact that was 
false.182 When explaining what might be an objective fact at odds with the use of clinical 
judgment, “a relator could present evidence that a certifying physician was not in fact, exercising 
the physician’s clinical judgment when certifying a patient’s medical condition, nor saw the 
patient, or that the physician did not actually believe that if the patient’s disease ran its normal 
course, the patient had a prognosis of six months or less.”183  
In a similar case also involving hospice care and inpatient services at a nursing home, a 
Court again did not allow the use of statistical sampling to prove liability for damages.184 In 
United States ex rel. Michaels v. Agape Senior Community, Inc., the Court felt that determining 
whether services for nursing home patients were medically necessary was a highly-fact intensive 
inquiry that involved review of patient files individually.185  Further, the Court did not find that 
statistical sampling could not be used in other cases, simply that this case was not “suited for 
statistical sampling.”186  
In United States v. AseraCare, the Court took issue with proving falsity using only 
difference of opinion by different medical experts in a case involving the certification of hospice 
patients for Medicare.187 The Court found “that contradiction based on clinical judgment or 
opinion alone cannot constitute falsity under the FCA as a matter of law.”188 The Court 
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highlighted other ways that the government could have proven falsity other than simply relying 
on the expert witness testimony, including providing evidence that information in patient files 
was false or that the physicians withheld information when certifying a patient for hospice.189 It 
is important that both the Vista Hospice Care and AseraCare Courts did not strictly prohibit 
statistical sampling or the use of expert testimony, but simply refused to allow only expert 
witness testimony to prove liability and falsity with the particular facts of their respective 
cases.190 
In a non-FCA case, United States v. Paulus, the government was able to overcome a 
subject judgment classification. In Paulus, the defendant physician was found guilty by a federal 
jury of making false statements and committing fraud when interpreting angiograms to show 
higher percentages of blockage.191 By interpreting the angiograms at a higher blockage 
percentage, of at least 70%, the physician did not need to complete any additional tests prior to 
inserting a stent.192 The District Court, after a guilty verdict by the jury, had granted the 
defendant’s motion for acquittal and a new trial, holding that the government did not prove intent 
and falsity.193 The District Court came to the conclusion that the “degree of stenosis” was a 
“subjective medical opinion” by an individual physician which cannot be confirmed or 
contradicted.194 The Sixth Circuit reversed the acquittal, reinstated the jury verdict and remanded 
the case, finding that “the degree of stenosis is a fact capable of proof or disproof,” it is not 
strictly a “subjective medical opinion” that cannot be proven or disproven.195 Stating that a 
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doctor who deliberately inflates the blockage he sees on an angiogram has told a lie; if he does so 
to bill a more expensive procedure, then he has also committed fraud.”196 Opinions and clinical 
judgments are not immune from being false if the person holding that belief knows that the facts 
do not support the opinion.197 The jury is the trier of fact and submitting the governments 
evidence to the jury is the appropriate method of determining proof.198 It is up to the jury to 
determine the weight to give the government’s evidence.199 The jury members were free to come 
to the conclusion that the physician had acted in good faith in reading angiograms or had not 
acted in good faith.200  The jury determines how reliable the expert witness is and how believable 
their testimony is for any given piece of evidence, each member of the jury can prevent a verdict 
in either direction.201 According to the Sixth Circuit, in this case the defendant was convicted for 
misrepresenting facts, he lied about the interpretations of the angiograms and then billed for 
unnecessary procedures.202 The Court stated that the time to challenge expert testimony is at a 
Daubert motion or during trial and here the defendant had multiple times to challenge the 
government’s evidence, which he did, and any one juror who had reasonable doubt could have 
prevented his conviction.203  
In United States ex rel. Loughren v. Unum Provident Corp., the Court found that the 
expert evidence and expert witness were unreliable since the expert’s report did not cite to any 
text that could support the methodology utilized nor could the expert, while testifying over his 
methodology, identify any peer-reviewed literature to support his approach.204 Further, in United 
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States ex rel. Loughren, the defense expert was able to credibly counter the government/relator’s 
expert witness which lead the Court to not trust the results.205 The Court quoted the First 
Circuit’s stance on Daubert, “as long as an expert’s scientific testimony rests upon “good 
grounds, based on what is known,” it should be tested by the adversary process – competing 
expert testimony and active cross-examination – rather than excluded from jurors’ scrutiny. 
…”206  In United States ex rel. Trim v. McKean, the Court did not extrapolate the findings of the 
audits to the universe of all claims because the Court found that the audits were “not a reliable or 
accurate representation of all . . . claims.”207  In Trim, the Court found the claims in Pennsylvania 
were not representative of the universe of claims since the charts were largely handwritten and 
illegible.208 The Oregon audit was unreliable since it was started in response to a lawsuit with the 
potential to recover claims.209 The Arizona audit was also unusable since the experts who were 
responsible for the audit did not testify.210   
In United States ex rel. El-Amin v. George Washington University, the Court did not 
allow statistical sampling because the discovery period was closed and the trial was starting.211  
The Court in El-Amin, found two issues with the government/relator’s request to use statistical 
sampling, (1) the timing and (2) unfairness to the defendant.212 The government/relator in that 
case had failed to raise the issue of statistical sampling during the discovery period which was 
now closed, failed to raise the issue in their pretrial statement as well as not raising the issue 
during a pretrial conference.213 Further, given that the trial was starting the defendant would be at 
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a disadvantage since they had not prepared for a trial using statistical sampling, had not sought 
out their own experts, nor determined the universe of claims.214  
In many cases, such as United States ex rel. Wall, United States ex. Rel. Michaels, and 
United States ex rel. Loughren, the Court has found the statistical method to be unreliable or 
unrepresentative. In United States ex rel. Loughren, the defendant was successful in attacking the 
government’s expert witness and his methods.215 The government’s expert witness did not direct 
the Court to any peer-reviewed literature in support of his methodology, therefore the Court was 
left with the defense expert witness’ criticisms of the methods utilized in the statistical sampling 
by the government.216 As indicated by the Court in AseraCare, the defendant can attack whether 
the government has met their burden and demand more than a simple battle of the experts in 
terms of establishing the requisite factors.217  
VII. Why Statistical Sampling Should be Allowed in health care FCA Cases 
The allowance of statistical sampling in FCA cases is beneficial to all parties since 
modern cases of health care fraud involve increasingly larger quantities of claims and there are 
high costs associated with individual claim-by-claim reviews.218 The FCA has been amended 
over time to ensure that the government can adequately fight fraudulent conduct.219 Allowing the 
use of statistical sampling is a furtherance of that goal to ensure that those receiving funds from 
the U.S. government are not engaging in fraudulent behaviors. Further, Statistical sampling 
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should be allowed in FCA cases so long as the government is able to meet their burden and prove 
that a defendant(s) engaged in fraudulent behavior.  
In several cases the Courts have found that the sampling methods or the samples 
themselves were not adequate and therefore would not allow the usage of the statistical sampling 
in the case.220 When a government/relator wants to use statistical sampling, they need to be 
prepared to prove that their expert witness is reliable and that the methodology utilized is reliable 
and credible in accordance with the Federal Rules of Evidence and the Daubert Factors. If a 
government/relator’s expert has based their methodologies and testimony off sufficient facts or 
data, the methods used are reliable because they have been tested and subjected to peer review, 
and variables have been controlled, then the expert testimony over statistical sampling should go 
to the fact finder to assess.221 
The government’s burden of proving that fraudulent actions have occurred is not 
minimalized by using statistical sampling. While the Courts do decide as a matter of law whether 
to allow statistical sampling, the weight given to the expert testimony, the statistical analysis, and 
the defendant’s or other witness’ testimony, belongs to the fact finder.222 In FCA cases the 
government/relator has the burden of proving their substantive theories, especially on falsity.223 
     Using statistical sampling is a reasonable solution if the government can specify falsity 
for each claim. If done with the appropriate methodology and care an audit and a representative 
sample will suffice to show fraudulent acts. Using statistical sampling methods to control for 
certain variables, such as patient conditions, caregivers, facilities, etc. that arise in any given 
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universe of claims, ensures that the appropriate parameters are factored into the analysis, 
therefore if the sample, using appropriate variables, proves falsity then extrapolation is logical.224    
     With the right parameters it would be reasonable to use statistical sampling in a case 
where the government/relator is proving that there was a systematic disregard for the truth. In 
such cases, statistical sampling is useful since the expert can control the analysis for many 
variables. A statistical sample that is representative of the universe of claims, in which different 
experts can testify to those factors does not defy what would occur with a case-by-case review. 
Using a representative sample, the government should be allowed to show that consistently 
altering your patient’s prognosis is fraudulent. The government needs to be prepared to connect 
evidence of objective falsehoods with the use of expert witness testimony in order to meet their 
burden of proof.225 If the government is claiming that a physician or care organization repeatedly 
and systematically saw one condition and repeatedly billed for another then the government 
should be able to call their own experts and present statistical analysis. The jury should decide 
which experts and testimony they believe are more reliable. Further, if you allow statistical 
sampling to be used to calculate damages under the FCA then to some extent you are also using 
it to prove liability.  So, there is no reason why you should not be able to use statistical sampling 
if you can use it to collect damages. 
The use of statistical sampling does not shift the burden of proving FCA elements to the 
defendant. Statistical sampling is based off a representative sample that can be utilized by both 
parties to show why or why not the required factors were met. There are several procedural 
safeguards that are available to a defendant to challenge the government’s use of statistical 
sampling. The defense can challenge the expert witness’ credentials and experience, the 
 
224 United States ex rel. Martin v. Life Care Ctrs. of America, Inc., 114 F. Supp. 3d 549, 566-67 (E.D. Tenn. 2014). 
225 United States ex rel. Wall, 2016 U.S. Dist. LEXIS 80160, at *63. 
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methodology utilized, the results themselves and also present their own evidence.226 When using 
Daubert motions or requesting summary judgment the defendant can challenge whether the 
sample itself is representative as well as challenge if the methods utilized were valid and 
representative of the universe of claims.227  
In addition to the multiple options of what a defendant can challenge there are several 
points during the litigation process that concerns can be raised, including during the pleading 
stage, pretrial hearings, and during the trial.228 A defendant has abundant opportunity to 
challenge the credibility of the government/relator’s witness and to present their own case 
including expert testimony, which ensures that their due process is protected despite using 
statistical sampling.229 As the provider of care, the defendant should be prepared to utilize their 
own data and have a good understanding of what data and information they have available to use 
in defending themselves.230 Once a defendant has notice provided in pleading, they can run their 
own analysis and evaluate their patient files.231 They have unlimited access to their own data and 
patient files to build their own case and develop their own analysis. 
 It is reasonable for the Court to allow the use of extrapolation to determine the total 
quantity of claims and the volume of damages, once the government/relator’s burden is met. 
Health care fraud will frequently involve numerous smaller claims, more so than other types of 
fraud cases under the FCA. When dealing with a large universe of claims it is reasonable and 
economical for both the government/relators and defendants to utilize some form of statistical 
sampling and extrapolation.  
 
226 United States ex rel. Martin, 114 F. Supp. 3d at 570. 
227 United States v. Robinson, No. 13-cv-27-GFVT, 2015 WL 1479396 (E.D. Ky. Mar. 31, 2015). 
228 United States ex rel. Martin, 114 F. Supp. 3d at 570. 
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As with any type of scientific data the key to using statistical sampling is the 
methodologies and data utilized. Statistical sampling that is valid, reliable, and credible should 
allay the Courts’ concerns. Health care fraud will continue to be an issue due to an aging 
population and changes in technology and medical care.232 In order to combat fraudulent 
behavior or to defend oneself when charged, statistical sampling should be part of the litigation 
toolbox and accepted by the Courts.  
 
232 U.S. CENSUS BUREAU, supra note 27; Deloitte, supra note 28.  
